Fish Oils.

The long-chain omega-3s in fish oil oxidize readily because of their many double bonds, and vitamin E is the fat-soluble antioxidant that intercepts that oxidation, which is why it is added to most fish oil softgels. A higher intake of these fatty acids also raises the body's ongoing need for vitamin E to keep them protected inside cell membranes.

Vitamin D is fat-soluble, so it is absorbed more completely when it dissolves into dietary fat and forms the mixed micelles the small intestine takes up. The oil in a fish oil capsule supplies that fat, which is why the two are common companions and why cod liver oil naturally carries both.

Astaxanthin is a fat-soluble antioxidant that sits in the same oil phase as the omega-3s and helps slow their oxidation, the role it plays naturally in krill oil. Astaxanthin itself needs dietary fat to be absorbed, so the oil doubles as the carrier that moves it into the body.

CoQ10 is lipophilic and depends on an oil phase to enter mixed micelles. Fish oil supplies that carrier.

Phospholipids disperse the oil into finer droplets so lipase has more surface. Long-standing practice in omega-3 emulsions.

DHA is carried mainly as phosphatidylcholine and choline supplies that head group. Both halves of the same membrane molecule.

Long-chain fatty acids enter mitochondria only as acylcarnitines, and carnitine is that carrier. It is the gate on normal long-chain fat oxidation.

Glutathione peroxidase is a selenoenzyme that reduces lipid hydroperoxides. A larger polyunsaturated load raises the peroxide it must clear.

Desaturase and elongase steps in fatty acid handling depend on zinc status. Low zinc slows that pathway.

Lutein is absorbed only when micellised with dietary fat. Co-dosing with an oil raises the absorbed fraction.

Rosemary diterpenes are the standard oil-phase antioxidant for marine oils. This protects the ingredient on the shelf.

Tocotrienols intercept peroxyl radicals in the lipid phase alongside tocopherol. They share the same chain-breaking job.

EPA shifts thromboxane output while ginkgolides antagonise platelet activating factor. Both nudge normal platelet function the same way and the effect adds.

Garlic organosulfur compounds lower aggregation by a route independent of eicosanoids. Together with EPA the effect on normal platelet function adds up.

Salicylate blocks platelet thromboxane synthesis, the very output EPA competes with as substrate. The two effects on normal platelet function stack.

Omega-6 gamma-linolenic acid and omega-3 fatty acids use the same desaturase and elongase enzymes and compete for phospholipid slots. A heavy omega-6 dose dilutes the omega-3 membrane profile.

Unbound iron catalyses peroxidation of long-chain polyunsaturated fat. High iron beside an unprotected oil favours rancidity chemistry.

Triglyceride oil must be hydrolysed by lipase before the fatty acids absorb. Added lipase supports that step when bile flow is modest.

EPA is elongated and desaturated through docosapentaenoic acid toward DHA, so a fish oil supplies both a finished product and a precursor for it. Conversion in adults is limited, which is why the finished DHA content of an oil matters rather than the total omega-3 number alone. Different oils carry very different EPA to DHA ratios.

EPA is the substrate for the E-series resolvins and competes with arachidonic acid at cyclooxygenase and lipoxygenase. Its share of a given fish oil varies with species and with how the oil was concentrated. Reading the EPA and DHA figures rather than the total oil weight is the practical point.

Long-chain triglycerides need bile salt micelles before pancreatic lipase products can be absorbed, so bile flow is a genuine limiter for marine oil uptake. Supplemental bile acids are used where that step is compromised. This is digestive physiology rather than a demonstrated increase in omega-3 status.

Pancreatic lipase cleaves the sn-1 and sn-3 positions of a triglyceride to leave a 2-monoacylglycerol for absorption. Ethyl ester omega-3 preparations are poorer substrates for that enzyme than triglycerides are, which is one reason meal fat matters more for them. Supplemental lipase addresses the hydrolysis step, not the transport step.

Taking a marine oil with dietary fat triggers bile release and raises the absorbed fraction substantially compared with an empty stomach. Medium-chain triglycerides are absorbed by a different route themselves but still contribute to the fat load that drives that response. The practical instruction is to take the oil with a meal.

Phospholipid emulsifiers pre-disperse the oil into fine droplets, increasing the surface area available to lipase and bile. Emulsified marine oil preparations are used for that reason and because they reduce the oily mouthfeel. The effect is on delivery, not on the fatty acids themselves.

Each double bond in EPA and DHA creates a bis-allylic site vulnerable to peroxidation, so tocopherols are added to marine oils to interrupt the chain reaction. The tocopherol is consumed doing this, which is why heavily oxidised oils also test low for it. Almost every fish oil softgel carries a tocopherol for this reason.

Krill delivers EPA and DHA largely bound to phospholipids rather than to triglycerides, which changes how they are packaged in the gut and carries choline along with them. Comparative absorption studies have reported differences in plasma appearance between the two carriers, and those studies measure a plasma marker rather than an outcome. Combining the two supplies the same fatty acids through two carriers.

DHA is concentrated at the sn-2 position of neuronal membrane phospholipids, and phosphatidylserine is one of the phospholipid classes that carries it. The pairing appears in cognitive formulas on that structural rationale. Combination trials specific to the pair are limited.

Omega-6 and omega-3 fatty acids compete for the same delta-6 desaturase and elongase enzymes, so a diet high in linoleic acid reduces conversion of alpha-linolenic acid onward to EPA. Preformed EPA and DHA from a marine oil bypass that bottleneck. The competition also plays out at the level of eicosanoid precursor pools in the membrane.

GLA is an omega-6 intermediate that uses the same elongase and desaturase steps as the omega-3 series. Supplying it alongside a marine oil pushes substrate into the omega-6 branch. Formulas combining the two usually keep the marine oil dose dominant for that reason.

High-dose marine omega-3 fatty acids modestly reduce platelet aggregation, and nattokinase has fibrinolytic activity of its own. Stacking two agents that act on normal clotting function is a combination to flag rather than to recommend, particularly around surgery or alongside prescribed anticoagulants. Anyone in that situation should raise it with their clinician.

Curcuminoids and long-chain omega-3 fatty acids both act on the arachidonic acid cascade, curcumin at the enzyme level and omega-3 by substrate displacement. The pairing is common in joint comfort formulas on that rationale. It also means the mild platelet effects of each are additive and worth flagging.

Ascorbate reduces the tocopheroxyl radical back to tocopherol at the water-lipid interface, sustaining the antioxidant that protects polyunsaturated fatty acids. The pairing matters more the higher the polyunsaturated load. It supports lipid stability rather than adding an omega-3 effect.

Free fatty acids form insoluble calcium soaps in the intestinal lumen, which is why large calcium doses taken with a fat load increase faecal fat excretion. With a triglyceride oil the effect is modest and dose dependent. Separating a large calcium dose from a large oil dose sidesteps it.

Taurine conjugates bile acids, and bile is what emulsifies long-chain fats for absorption. Taurine and DHA are also both concentrated in retinal and cardiac tissue. The absorption link is mechanistic; the tissue overlap is descriptive rather than a demonstrated interaction.